Home » Stocks » IDYA

IDEAYA Biosciences, Inc. (IDYA)

Stock Price: $18.61 USD -0.09 (-0.48%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 600.36M
Revenue (ttm) 19.54M
Net Income (ttm) -34.50M
Shares Out 24.72M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE 4.65
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $18.61
Previous Close $18.70
Change ($) -0.09
Change (%) -0.48%
Day's Open 18.61
Day's Range 17.41 - 19.00
Day's Volume 584,888
52-Week Range 4.39 - 24.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., April 16, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

2 days ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

2 days ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

3 days ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -2.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

3 weeks ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

3 weeks ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

1 month ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and devel...

1 month ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 /PRNewswire/ --IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

1 month ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and devel...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 8, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

4 months ago - PRNewsWire

IDEAYA Biosciences (IDYA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

7 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -126.34% and -100.00%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

8 months ago - PRNewsWire

IDEAYA Biosciences (IDYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

8 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...

9 months ago - PRNewsWire

A high-profile partnership and a promising pipeline of oncology-focused treatments suggest favorable reward-versus-risk in IDYA stock. The post Target Breakthrough Science and Medicine with Ideaya Biosc...

9 months ago - InvestorPlace

Here's what pushed up shares of the highest-flying healthcare stocks.

Other stocks mentioned: CLDX, QDEL
9 months ago - The Motley Fool

The development-stage drug developer is selling common stock to raise cash. It's a wise move.

9 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock ...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an ...

10 months ago - PRNewsWire

IDEAYA Biosciences (NASDAQ: IDYA) shares are trading higher on Tuesday, after the company, along with GSK, announced a partnership in Synthetic Lethality.

10 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif. and LONDON, June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an em...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted...

10 months ago - PRNewsWire

IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 8, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 19, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted ...

11 months ago - PRNewsWire

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients wit... [Read more...]

Industry
Biotechnology
IPO Date
May 23, 2019
CEO
Yujiro Hata
Employees
62
Stock Exchange
NASDAQ
Ticker Symbol
IDYA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is 29.11, which is an increase of 56.42% from the latest price.

Price Target
$29.11
(56.42% upside)
Analyst Consensus: Strong Buy